Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80000 participants
OBSERVATIONAL
2020-01-01
2021-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Weight estimation with ultrasound is performed only on indication; stagnant or deplaning SF dimensions or in the event of complications. Only high-risk pregnancies have repeated growth checks during pregnancy from the beginning.
There are potential benefits to detecting IUGR fetuses during pregnancy. Still, the effect is questioned. A meta-analysis of randomized studies could not benefit from a routine ultrasound in the third trimester.
The scientific purpose of this work is to evaluate the benefits of early detection and care of SGA (small for gestational age)/IUGR (growth-inhibited) fetuses and, if possible, to increase knowledge about this patient group. The hope is that this will lead to a better opportunity to personalize both preventive care and treatment of these women and children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death
NCT02148055
Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study
NCT01981824
Comparative Study of the Propagation of Uterine Electrical Activity (EHG) in Pregnant Women During Pregnancy and During Labour
NCT02814344
Improving Detection of Fetuses at Risk - Who Needs Systematic Training?
NCT03105544
Predictors of Intrauterine Growth Restriction
NCT03349671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. HIE (hypoxic-ischemic encephalopathy)2-3 (neonatal convulsions in the fetus after childbirth),
2. Intracranial hemorrhage,
3. Apgar score \< 4 at 5 minutes,
4. Arterial umbilical cord pH (potential of hydrogen) \< 7.10,
5. Intrauterine fetal death, 6)intrapartal death.
Inclusion: All pregnancies in Stockholm with a fetus, born between 2014 and 2017 and without chromosomal abnormalities or other structural abnormalities, will be included in the project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early / growth restriction
Intrauterine growth restriction with onset before 32 weeks of gestation
ultrasound
An extra ultrasound performed during pregnancy
Late growth restriction
Intrauterine growth restriction with onset after 32 weeks of gestation
ultrasound
An extra ultrasound performed during pregnancy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ultrasound
An extra ultrasound performed during pregnancy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eva Wiberg-Itzel
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva Wiberg-Itzel, PhD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institute Sodersjukhuset Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eva Wiberg-Itzel
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Early or late IUGR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.